Moderna pens deal with China to make mRNA medicines that 'will not be exported'
Moderna signed a deal Wednesday to develop and manufacture mRNA medicines in China, after other US and European Covid-19 drugmakers struggled to break into the market without a Chinese partner.
Under the agreement, the Cambridge, MA vaccine developer will produce medicines in China that “will be exclusively for the Chinese people” and “will not be exported,” according to an emailed statement from Moderna.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.